Reducing the Burden of Chemoradiotherapy with the Combination of Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma

Authors

Jessica Hochberg, New York Medical CollegeFollow
Jaclyn Basso
Liana Klejmont, New York Medical CollegeFollow
Lauren Harrison, New York Medical CollegeFollow
Allyson M. Flower, New York Medical CollegeFollow
Aliza Gardenswartz, New York Medical CollegeFollow
Qiuhu Shi, New York Medical CollegeFollow
Perry Gerard, New York Medical CollegeFollow
Mitchell S. Cairo, New York Medical CollegeFollow

Author Type(s)

Faculty

Document Type

Abstract

Publication Date

2019

DOI

10.1182/blood-2019-128684

Journal Title

Blood

Department

Pediatrics

Second Department

Medicine

Third Department

Biostatistics

Recommended Citation

Hochberg, J., Basso, J., Klejmont, L., Harrison, L., Flower, A. M., Gardenswartz, A., Shi, Q., Gerard, P., & Cairo, M. S. (2019). Reducing the Burden of Chemoradiotherapy with the Combination of Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma. Blood, 134 (Suppl. 1), 127. https://doi.org/10.1182/blood-2019-128684